Nyxoah reports preliminary Q2 revenue EUR 1.3M

Reports preliminary Q2 operating expenses EUR 20.7M. “We are pleased with the growth we saw in the second quarter, which provides further evidence that our commercial proof of concept in Germany has been successful,” commented Olivier Taelman, CEO. “With FDA approval in hand, we expect to take the lessons learned from Germany and apply them to the U.S. as we bring our unique Genio system to the U.S. In addition, we believe that the patient population currently enrolled in the ACCCESS study will provide statistically significant results, which along with the outcomes from prior clinical evidence, will provide meaningful data with respect to the safety and efficacy of using Genio therapy in the patient population suffering from Complete Concentric Collapse. Patients with CCC represent a significant unmet need in the treatment of OSA as no FDA approved treatment currently exists.”